Skip to main content


for people ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion:



Cabazitaxel will be administered 20 mg/m2 IV over 1 hour every 3 weeks, as is the standard administration dose and schedule. This application is a non-labeled indication for cabazitaxel and will inform future drug development in gastroesophageal malignancies, where docetaxel remains an approved first line agent, but is not routinely used due to excessive toxicity and marginal efficacy. At the conclusion of this study, we hope to demonstrate activity of single agent cabazitaxel in refractory gastric cancer, with preferential activity in one or more gastric cancer subtypes

Official Title

An Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma


Prior to initiating protocol therapy, patients will undergo screening evaluations, to be done within 30 days of protocol initiation unless otherwise noted.

Patients who are taxane naïve will be assigned to arm A and patients who have had prior taxane therapy will be assigned to Arm B. Each arm will be analyzed separately for the primary study endpoint of 3 month progression free survival rate (PFS), as defined as the time from the start of treatment to the date of disease progression or death. Cabazitaxel will be administered 20 mg/m2 IV over 1 hour every 3 weeks.

In the absence of treatment delays due to adverse event(s), treatment may continue until disease progression; intercurrent illness that prevents further administration of treatment; unacceptable adverse event(s); patient decides to withdraw; general or specific changes in the patient's condition render the patient unacceptable for further treatment in the judgment of the investigator.

Patients will be followed for 6 months after removal from study or until death, whichever occurs first. Patients removed from study for unacceptable adverse events will be followed until resolution or stabilization of the adverse event.


Gastric Adenocarcinoma Gastroesophageal Adenocarcinoma Distal Esophageal Adenocarcinoma Gastric Cancer Adenocarcinoma Esophageal Neoplasms Taxane


You can join if…

Open to people ages 18 years and up

  1. Subject must have histologically or cytologically confirmed gastric, or gastroesophageal adenocarcinoma, or distal esophageal adenocarcinoma.
  2. Subject must have unresectable or metastatic gastroesophageal adenocarcinoma.
  3. Subject must have evaluable disease as per RECIST criteria.
  4. Subject must have had at least one prior cytotoxic chemotherapy regimen for unresectable or metastatic disease. Prior taxane therapy is allowed.
  5. Age >/=18 years old.
  6. ECOG performance status status >/= 2
  7. Subject must have normal organ and marrow function as defined below:
  8. WBC >/= 3,000/uL
  9. Total Bilirubin ≤ 1.5 x upper limits of normal
  10. AST (SGOT) ≤ 2.5 x upper limits of normal
  11. ALT (SGPT) ≤ 2.5 x upper limits of normal
  12. Hgb > 7.5 g/dl (without transfusion within 7 days)
  13. ANC > 1000 /ml
  14. Plt > 75 K/ml (without transfusion)
  15. Creatinine < 2.0 g/dl or a calculated creatinine clearance > 45/cc (using Cockroft-Gault formula)

  16. Women of child-bearing potential and men must agree to use adequate contraception(hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. 10. Ability to understand and the willingness to sign a written informed consent document.

You CAN'T join if...

  1. Subject with previously untreated unresectable or metastatic gastroesophageal adenocarcinoma.
  2. Subject with more than 2 prior cytotoxic therapies (not including treatment administered for locally curable disease) for unresectable or metastatic gastroesophageal adenocarcinoma.
  3. Subject with CNS metastases with active neurologic dysfunction. These patients are excluded because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse event.
  4. Significant medical co-morbidity that would preclude safe administration of cytotoxic therapy, including but not limited to:

a.Cardiac disease i. Unstable angina ii. Myocardial infarction < 3 months prior to study initiation b. Ongoing serious infection i. Bacteremia or sepsis requiring intravenous antibiotics ii. HIV with AIDS defining illness c.Inadequate oral nutritional intake i. Requirement for daily intravenous fluids or total parenteral nutrition. d. Psychiatric illness/social situations that would limit compliance with study requirement

  1. Subject who has had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from prior treatment related toxicity with persistent symptoms >/= grade 2 due to agents administered more than 4 weeks earlier.
  2. Subject may not receive another investigational agent.
  3. History of allergic reactions attributed to compounds of similar chemical or biologic composition to Cabazitaxel, or to drugs formulated with polysorbate 80.
  4. Pregnant (positive pregnancy test) and lactating women are excluded from the study because the risks to an unborn fetus or potential risks in nursing infants are unknown.


  • UCSF Comprehensive Cancer Center
    San Francisco, California, 94115, United States
  • Karmanos Cancer Institute
    Detroit, Michigan, 48201, United States
  • Weill Cornell Medical College
    New York, New York, 10065, United States
  • Yale University
    New Have, Connecticut, 06510, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts, 02215, United States


in progress, not accepting new patients
Start Date
Completion Date
Weill Medical College of Cornell University
Phase 2
Lead Scientist
Andrew Ko
Study Type
Last Updated
February 28, 2017